SG11201809677XA - Cd200 mutant and its uses - Google Patents

Cd200 mutant and its uses

Info

Publication number
SG11201809677XA
SG11201809677XA SG11201809677XA SG11201809677XA SG11201809677XA SG 11201809677X A SG11201809677X A SG 11201809677XA SG 11201809677X A SG11201809677X A SG 11201809677XA SG 11201809677X A SG11201809677X A SG 11201809677XA SG 11201809677X A SG11201809677X A SG 11201809677XA
Authority
SG
Singapore
Prior art keywords
international
lane
protein
blenheim
freeland
Prior art date
Application number
SG11201809677XA
Other languages
English (en)
Inventor
Philip Huxley
Joseph Sheridan
Jonathan Heal
Original Assignee
Ducentis Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ducentis Biotherapeutics Ltd filed Critical Ducentis Biotherapeutics Ltd
Publication of SG11201809677XA publication Critical patent/SG11201809677XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201809677XA 2016-05-10 2017-05-10 Cd200 mutant and its uses SG11201809677XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1608197.8A GB201608197D0 (en) 2016-05-10 2016-05-10 Novel proteins
PCT/GB2017/051303 WO2017194941A1 (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Publications (1)

Publication Number Publication Date
SG11201809677XA true SG11201809677XA (en) 2018-11-29

Family

ID=56297468

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809677XA SG11201809677XA (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Country Status (15)

Country Link
US (1) US11203628B2 (ja)
EP (1) EP3455247A1 (ja)
JP (1) JP6997767B2 (ja)
KR (2) KR102498901B1 (ja)
CN (1) CN109219614B (ja)
AU (1) AU2017264825B2 (ja)
BR (1) BR112018073280A2 (ja)
CA (1) CA3023601A1 (ja)
EA (1) EA201892554A1 (ja)
GB (1) GB201608197D0 (ja)
IL (1) IL262846B2 (ja)
MX (1) MX2018013778A (ja)
SG (1) SG11201809677XA (ja)
WO (1) WO2017194941A1 (ja)
ZA (1) ZA201807079B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
KR102186780B1 (ko) 2019-02-18 2020-12-04 박주현 비행부와 탑승부를 분리하여 축으로 결합한 유인드론
CN110859951A (zh) * 2019-09-23 2020-03-06 中国药科大学 Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用
GB202115803D0 (en) * 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
WO2023214388A1 (en) * 2022-05-06 2023-11-09 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
WO2023214387A1 (en) * 2022-05-06 2023-11-09 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202303291D0 (en) 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE319825T1 (de) * 1997-11-07 2006-03-15 Trillium Therapeutics Inc Verfahren und zusammensetzungen zur immunomodulation
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
CA2369454A1 (en) 1999-04-13 2000-10-19 Schering Corporation Uses of mammalian ox2 protein and related reagents
CA2402293A1 (en) * 2000-03-07 2001-09-13 Hyseq, Inc. Novel nucleic acids and polypeptides
ATE406385T1 (de) 2000-11-22 2008-09-15 Trillium Therapeutics Inc Verkürztes cd200
WO2007024715A2 (en) * 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
JP2010515751A (ja) 2007-01-11 2010-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cd200およびそのレセプターcd200rは破骨細胞の分化を介して骨質量を調節する
US8753639B2 (en) * 2009-03-31 2014-06-17 University Of Washington Through Its Center For Commercialization Compositions and methods for modulating the activity of complement regulatory proteins on target cells
CA2786692A1 (en) * 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Also Published As

Publication number Publication date
CN109219614A (zh) 2019-01-15
EA201892554A1 (ru) 2019-04-30
CN109219614B (zh) 2022-05-24
IL262846B (en) 2022-10-01
JP2019518788A (ja) 2019-07-04
US20190367580A1 (en) 2019-12-05
KR20230025937A (ko) 2023-02-23
EP3455247A1 (en) 2019-03-20
ZA201807079B (en) 2019-07-31
AU2017264825B2 (en) 2021-04-08
IL262846A (en) 2018-12-31
AU2017264825A1 (en) 2018-11-15
KR102689460B1 (ko) 2024-07-26
CA3023601A1 (en) 2017-11-16
WO2017194941A1 (en) 2017-11-16
BR112018073280A2 (pt) 2019-03-19
KR102498901B1 (ko) 2023-02-10
IL262846B2 (en) 2023-02-01
US11203628B2 (en) 2021-12-21
JP6997767B2 (ja) 2022-03-04
MX2018013778A (es) 2019-08-01
KR20190003761A (ko) 2019-01-09
GB201608197D0 (en) 2016-06-22

Similar Documents

Publication Publication Date Title
SG11201809677XA (en) Cd200 mutant and its uses
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201903674YA (en) Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201908650PA (en) Optimized antibody compositions for treatment of ocular disorders
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201907422RA (en) Anti-tau antibodies and methods of use thereof
SG11201804294WA (en) Tank-binding kinase inhibitor compounds
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201803642WA (en) Bacteria-based protein delivery
SG11201808830YA (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201903348UA (en) Therapeutic compounds and methods of use thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201806852PA (en) Protein purification
SG11201804589TA (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
SG11201909793YA (en) AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds